Precision medicine company Natera Inc (NASDAQ: NTRA) on Wednesday announced the presentation of new clinical evidence supporting its Prospera test across 17 abstracts, including six oral presentations, at the 2026 International Society for Heart and Lung Transplantation Annual Meeting, highlighting its role in improving detection, risk stratification and clinical decision-making in transplant care.

In heart transplantation, data from the ProTECT and DEFINE-HT studies showed that Prospera Heart dynamics predicted adverse outcomes within one year post-transplant, with positive results associated with up to fourfold higher risk of complications including graft dysfunction, rejection, hospitalisation or death. The test also influenced clinical management decisions in more than 30% of cases and demonstrated improved performance with reduced false positives in the TRIFECTA-Heart study.

In lung transplantation, findings indicated that Prospera Lung can detect infection, chronic lung allograft dysfunction and early graft injury, including cases not identified by biopsy. Elevated test results above standard thresholds were linked to increased risk of adverse outcomes, with evidence suggesting preemptive treatment may improve patient measures such as lung function. Additional data showed the test's utility in monitoring graft injury related to gastroesophageal reflux, with measurable improvement following surgical intervention.

Natera highlighted Prospera's expanding clinical utility across both heart and lung transplantation, supported by real-world data and multiple independent studies presented throughout the event.